Rachel Miller – Grants & Contracts — University of Kentucky

Research activity per year

If you made any changes in Pure these will be visible here soon.

5 Active
24 Finished

5 results

Filter

Active

IMGN853-0421/GOG-3078: Randomized, Multicenter, Open-label, Phase 3 study of Mirvetuximab Soravtansine in Combination with Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients with FRa-positive Recurrent Platinum-sensitive Epithelial o
Miller, R.
ImmunoGen Inc
8/30/23 → 8/30/25
Project: Research project
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-Mutated Advanced Epithelial Ovarian Cancer (EOC)
Miller, R.
Gynecological Oncology Group Foundation Incorporated
2/27/20 → 8/24/24
Project: Research project
A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-Paclitaxel Versus Placebo Plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Miller, R.
Gynecological Oncology Group Foundation Incorporated
11/15/19 → 1/16/24
Project: Research project
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel with or without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Newly Diagnosed Subjects with Previously Untreated Stages III or IV High-Grade Serious Epithelial Ovarian,
Ueland, F., Baldwin Branch, L., Desimone, C. & Miller, R.
Gynecological Oncology Group Foundation Incorporated
12/23/15 → 7/4/24
Project: Research project
Member Institution Purchased Service Agreement
Miller, R. & Romond, E.
NRG Oncology Foundation Incorporated
3/1/14 → 1/4/24
Project: Research project

Your message has successfully been sent.

Your message was not sent due to an error.